reason report
pt
bottom line updat model follow
result reiter op rate price target increas
call manag highlight valu
custom place high-touch value-add model
busi continu grow well driven end-market demand
encourag dental market appear stabl
grow consum sale growth y/i
strongest sinc impress na dental local
intern growth y/i follow growth
recent announc clear-align system expect
launch us expand geographi earli
manag rais adj ep guidanc slightli
continu see buyback save restructur
potenti earn boost believ end-market
healthi compani retain leadership posit
maintain op rate pt increas
guidanc rais slightli adj ep guidanc
increas slightli y/i
compar prior leerink/consensu
guid includ impact previous announc one-
time cash bonu certain employe exclud cost relat
restructur spin-off anim health expect late
tax rate remain share
outlin manag continu expect anim health spin-off
merger vet first choic close though possibl
close could slip manag cite unpredict
time registr review process sec relat
deal manag explain capit alloc
prioriti consist prioriti past
manag intend alloc fund repurchas share fund
work capit though good oper cash flow project suggest
may minim alloc target invest short-to-
medium term would includ geograph expans medic
dental segment enhanc market penetr distribut
promot value-bas servic effort could
provid boost ep
net debt total capit
compani inform leerink partner llc research
revenu billion dollar
ep adjust non-recur item
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
dental segment continu strengthen robust cad/cam
sale impress anoth strong quarter dental
segment amid commentari manag stabl market
manag believ take share dental
consum intern growth y/i strongest sinc
equip side sale growth y/i good
especi consid tough comp follow growth rate
y/i cad/cam sale strong quarter sale
north america partial off-set weaker-than-expect
digit x-ray imag sale overal consolid dental sale
quarter good y/i beat leerink/
consensu encourag y/i na
local intern dental growth rate compar
encourag continu commentari market stabil
view high equip growth rate indic dental offic
believ busi perform well
medic result solid support north america
intern growth medic revenu y/i beat
leerink/consensu manag attribut
strength medic solid organ growth exist larg custom
 local intern growth y/i impress grew bp
q/q local intern growth also strong rebound
nice growth rate
strongest sinc manag highlight believ
high-touch consult approach allow take share
anim health intern growth lead
segment anim health sale y/i beat leerink/
consensu driven strong intern sale
grew y/i na anim intern sale growth
decent show anoth quarter deceler rel
howev normal impact transit direct
agenc sale intern growth would accord
manag normal rate robust
repres slight declin rel normal growth
rate local intern growth strong
highest rate growth sinc overal remain impress
perform anim health segment continu believ
end market remain healthi attract
comment restructur effort call
manag provid detail recent announc
restructur effort compani expect incur one-tim cost
restructur initi expect
averag payback period month target area includ
reduc redund activ result prior acquisit
tweak estim maintain op increas revenu
estim slightli reflect strong perform dental anim
sale adj ep estim stand
estim increas remain current
share repurchas author well cash
larg dividend come anim health spin view
earn could see boost capit deploy either share
repurchas maintain outperform rate
pt increas
inc one largest distributor medic dental veterinari suppli
office-bas practic throughout world major compani busi base
dental suppli anim health physician offic practic distributor
north america europ australia/new zealand dental anim health
market enjoy top qualiti servic mark custom medacorp survey
organ growth rate sever compani divis modest recent
reacceler make us posit compani on-going acquisit strategi
drive accret furthermor expect multipl compress stock
experienc recent month revers investor realiz margin
distant threat worri around ftc suit wane continu solid execut quarterli
result time result sentiment shift multipl expans trough level
result rate share outperform
current trade ep premium drug
distribut pbm group esrx next
month expect share trade ep would
put stock price target valuat would roughli line stock
year histor averag ntm ep therefor reason view especi
given hsic consist abil grow market share deliv upsid expect
acquisit believ current multipl alreadi reflect improv sentiment
risk/reward profil improv substanti
competit relianc manufactur healthcar distribut industri north
america intern highli competit distributor compet basi price
product offer custom servic valu ad product servic competitor obtain
exclus right manufactur distribut certain product manufactur bypass
distributor altogeth could advers impact earn larg competitor
especi abroad use size increas price pressur group purchas
organ gpo larg provid may also demand lower price addit
manufactur disrupt shortag result unabl meet custom
demand certain product seen flu vaccin shortag issu
supplier relationship advers impact firm earn
acquisit restructur one largest player alternate-car market
made numer acquisit domest intern market
acquisit joint ventur involv numer risk may integr well
manag intend success integr acquisit past
immedi short-term impact bottom line drag earn year
come acquisit may result loss custom product line acquir busi
may unintend effect area oper cost increas relat
restructur integr new busi advers impact firm
earn margin
season quarterli fluctuat tradit sale higher third
fourth quarter result end year custom purchas pattern well flu
season ill quarterli earn impact number factor includ
sever flu season product avail time price chang product releas
vendor advers impact revenu firm
govern regul healthcar reform custom
healthcar industri highli regul local state feder law firm may need
adapt procedur price result polici chang govern agenc
pressur reduc budget deficit balloon healthcar cost frequent target
enact healthcar reform reduct reimburs rate public and/or
privat insur program could advers impact revenu profit margin foreign
domest tax law also subject chang current interpret subject
scrutini challeng could advers impact firm earn
ftc litig su ftc alleg price collus
believ like outcom complaint settlement possibl
complaint could expand grow crimin charg expand area
revenu
revenu
revenu
net sale
adjust incom tax
incom tax
equiti incom affili
adjust incom cont op
net incom cont op
ep continu oper
adjust ep continu oper
